Coverage
-
January 26, 2018
An Illinois federal jury on Friday rejected an Arizona man's claims that AbbVie Inc.’s AndroGel caused his pulmonary embolism, handing a win to AbbVie in its third bellwether trial in the multidistrict litigation over testosterone replacement therapy drugs.
3 other articles on this case.
View all »